Literature DB >> 310815

A sulfone beta-lactam compound which acts as a beta-lactamase inhibitor.

N Aswapokee, H C Neu.   

Abstract

CP-45,899 [3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3,2,0)heptane-2-carboxylic acid, 4,4-dioxide [2S-(2alpha,5alpha)]] has low intrinsic activity against most Gram-positive cocci, Enterobacteriaceae and Pseudomonas. It inhibits Neisseria at concentrations of 0.1 approximately 6.2 microgram/ml. The combination of CP-45,899 and ampicillin inhibited Staphylococcus aureus and Enterobacteriaceae resistant to ampicillin by virtue of beta-lactamase activity. Combination of CP-45,899 and cephalothin was synergistic less often, and CP-45,899 did not act synergistically with carbenicillin or ticarcillin against Pseudomonas resistant to these agents. CP-45,899 acted synergistically with ampicillin against Bacteroides. Synergy of CP-45,899 and ampicillin was demonstrated at varying concentrations suggesting that it may significantly enlarge the antibacterial activity of ampicillin against resistant bacteria.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 310815     DOI: 10.7164/antibiotics.31.1238

Source DB:  PubMed          Journal:  J Antibiot (Tokyo)        ISSN: 0021-8820            Impact factor:   2.649


  20 in total

1.  In vitro effects of beta-lactams combined with beta-lactamase inhibitors against methicillin-resistant Staphylococcus aureus.

Authors:  S Kobayashi; S Arai; S Hayashi; T Sakaguchi
Journal:  Antimicrob Agents Chemother       Date:  1989-03       Impact factor: 5.191

2.  Proposed changes in interpretive criteria and potency of ampicillin and ampicillin-sulbactam disks for susceptibility tests.

Authors:  A L Barry; R N Jones
Journal:  J Clin Microbiol       Date:  1988-04       Impact factor: 5.948

3.  Clinical experience with intramuscular sulbactam/ampicillin in the outpatient treatment of various infections. A multicentre trial.

Authors:  M F Güneren
Journal:  Drugs       Date:  1988       Impact factor: 9.546

4.  Activity of cefoperazone and two beta-lactamase inhibitors, sulbactam and clavulanic acid, against Bacteroides spp. correlated with beta-lactamase production.

Authors:  M A Crosby; D W Gump
Journal:  Antimicrob Agents Chemother       Date:  1982-09       Impact factor: 5.191

5.  Synergistic activity of mecillinam in combination with the beta-lactamase inhibitors clavulanic acid and sulbactam.

Authors:  H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1982-09       Impact factor: 5.191

6.  Inconsistency of synergy between the beta-lactamase inhibitor CP-45,899 and beta-lactam antibiotics against multiply drug-resistant Enterobacteriaceae and pseudomonas species.

Authors:  R J Fass
Journal:  Antimicrob Agents Chemother       Date:  1981-02       Impact factor: 5.191

7.  Interpretive standards and quality control limits for susceptibility tests with ampicillin-sulbactam combination disks.

Authors:  A L Barry; R N Jones; C Thornsberry
Journal:  J Clin Microbiol       Date:  1984-02       Impact factor: 5.948

8.  In vitro evaluations of aminopenicillin/beta-lactamase inhibitor combinations.

Authors:  R N Jones
Journal:  Drugs       Date:  1988       Impact factor: 9.546

9.  beta-Lactamase inhibitory activity of iodopenicillanate and bromopenicillanate.

Authors:  H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1983-01       Impact factor: 5.191

10.  Synergistic activity of piperacillin in combination with beta-lactamase inhibitors.

Authors:  H C Neu; K P Fu
Journal:  Antimicrob Agents Chemother       Date:  1980-10       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.